{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:30:50Z","timestamp":1787671850189,"version":"build-2736575974"},"reference-count":152,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Triple-negative breast cancer (TNBC) represents a highly aggressive breast cancer subtype characterized by the absence of estrogen receptor, progesterone receptor, and HER2 expression, resulting in limited targeted therapeutic options and poor clinical outcomes. Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of TNBC, therapeutic responses remain restricted to a subset of patients due to substantial heterogeneity within the tumor immune microenvironment (TIME). Increasing evidence indicates that immune evasion in TNBC is driven by complex interactions among tumor cells, immune populations, stromal components, and metabolic alterations. This review summarizes the dynamic landscape of the TNBC immune microenvironment, focusing on the functional roles of tumor-infiltrating lymphocytes, tumor-associated macrophages, tumor-associated neutrophils, natural killer cells, and myeloid-derived suppressor cells in regulating antitumor immunity and therapeutic resistance. We further discuss clinical advances of ICIs, including monotherapy and chemoimmunotherapy approaches, as well as emerging therapeutic strategies involving small molecules, bispecific antibodies, antibody\u2013drug conjugates, and novel immune-based modalities.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1887760","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:53:20Z","timestamp":1787669600000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Decoding the tumor microenvironment of triple-negative breast cancer: from immune evasion to precision immunotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Hongyu","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Shengjing Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meicheng","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shengjing Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuepeng","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shengjing Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shengjing Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: Pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res"},{"key":"B3","article-title":"Metronomic chemotherapy response in MDA-MB-231 triple-negative breast cancer cells under nicotine exposure","volume":"49","author":"Espa\u00f1ol","year":"2025"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.20944\/preprints202306.0074.v1","article-title":"Triple negative breast cancer treatment options and limitations: Future outlook","volume":"15","author":"Obidiro","year":"2023","journal-title":"Pharmaceutics"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1405491","article-title":"Advancements and challenges in triple-negative breast cancer: A comprehensive review of therapeutic and diagnostic strategies","volume":"14","author":"Xiong","year":"2024","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70803","article-title":"Targeting triple-negative breast cancer: Resistance mechanisms and therapeutic advancements","volume":"14","author":"Raman","year":"2025","journal-title":"Cancer Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.650491","article-title":"Tumor mutation burden and immune invasion characteristics in triple negative breast cancer: Genome high-throughput data analysis","volume":"12","author":"Gao","year":"2021","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s40364-024-00714-6","article-title":"Tumor microenvironment and immunotherapy for triple-negative breast cancer","volume":"12","author":"Guo","year":"2024","journal-title":"biomark Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.3390\/ijms26062795","article-title":"Tumor microenvironment dynamics of triple-negative breast cancer under radiation therapy","volume":"26","author":"Niture","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41523-023-00541-2","article-title":"A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st\/2nd line metastatic triple-negative breast cancer","volume":"9","author":"Page","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1817652116","article-title":"Infiltration of CD8(+) T cells into tumor cell clusters in triple-negative breast cancer","volume":"116","author":"Li","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br J Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.3390\/ijms23031833","article-title":"Granzymes: The molecular executors of immune-mediated cytotoxicity","volume":"23","author":"Hay","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.17281","article-title":"CD8-positive T-cells are key immune cells for predicting the therapeutic effect of neoadjuvant chemotherapy in triple-negative breast cancer","volume":"44","author":"Uenaka","year":"2024","journal-title":"Anticancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03157-w","article-title":"Targeting transforming growth factor-\u03b22 by antisense oligodeoxynucleotide accelerates T cell-mediated tumor rejection in a humanized mouse model of triple-negative breast cancer","volume":"71","author":"Lee","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189193","article-title":"CD8(+) T-cell exhaustion: Impediment to triple-negative breast cancer (TNBC) immunotherapy","volume":"1879","author":"Feng","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adj7808","article-title":"Interferon-induced senescent CD8(+) T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancer","volume":"17","author":"Fu","year":"2025","journal-title":"Sci Transl Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1507283","article-title":"CD8(+) T cell exhaustion in the tumor microenvironment of breast cancer","volume":"15","author":"Xie","year":"2024","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1117092","article-title":"IL-15 promotes self-renewal of progenitor exhausted CD8 T cells during persistent antigenic stimulation","volume":"14","author":"Lee","year":"2023","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adg0539","article-title":"PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for their accelerated differentiation into effectors","volume":"8","author":"Gill","year":"2023","journal-title":"Sci Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2024.106637","article-title":"Tumor-derived exosomal ICAM1 promotes bone metastasis of triple-negative breast cancer by inducing CD8+ T cell exhaustion","volume":"175","author":"Chen","year":"2024","journal-title":"Int J Biochem Cell Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cell.2023.02.021","article-title":"Dynamic CD8(+) T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes","volume":"186","author":"Rahim","year":"2023","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.ccell.2023.01.004","article-title":"Intratumoral CD8(+) T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer","volume":"41","author":"Virassamy","year":"2023","journal-title":"Cancer Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.17667","article-title":"The potential role of CD8+ cytotoxic T lymphocytes and one branch connected with tissue-resident memory in non-luminal breast cancer","volume":"12","author":"Zhao","year":"2024","journal-title":"PeerJ"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02807-1","article-title":"Comprehensive genomic and immunophenotypic analysis of CD4 T cell infiltrating human triple-negative breast cancer","volume":"70","author":"Zhang","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2549-3","article-title":"Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers","volume":"139","author":"Hong","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"B29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/cancers13030373","article-title":"Modulation of CD4 T cell response according to tumor cytokine microenvironment","volume":"13","author":"Accogli","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.3056","article-title":"Tumor-infiltrating lymphocytes in triple-negative breast cancer","volume":"331","author":"Leon-Ferre","year":"2024","journal-title":"Jama"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.crc-26-0304","article-title":"CD4+ T cells sensitize quasimesenchymal breast tumors lacking CD73 to anti-CTLA4 immune checkpoint blockade therapy","volume":"6","author":"Chandraganti","year":"2026","journal-title":"Cancer Res Commun"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3390\/cancers18081295","article-title":"Hyperthermia combined with anti-CTLA-4 antibody induces tumor microenvironment remodeling involving CD4(+) T cells in local and distant antitumor effects in a murine triple-negative breast cancer","volume":"18","author":"Okuuchi","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110346","article-title":"Codelivery of triptolide and IFN-\u03b3 to boost antitumor immunity for triple-negative breast cancer","volume":"120","author":"Cai","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3390\/vaccines13050525","article-title":"Identification and validation of Th1-selective epitopes derived from proteins overexpressed in breast cancer stem cells","volume":"13","author":"Cecil","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2024.104805","article-title":"PIM kinase inhibitor AZD1208 in conjunction with Th1 cytokines potentiate death of breast cancer cellsin vitrowhile also maximizing suppression of tumor growthin vivo when combined with immunotherapy","author":"Anwar","year":"2024","journal-title":"Cell Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"8592","DOI":"10.1038\/s41467-024-52577-y","article-title":"Tumor draining lymph nodes connected to cold triple-negative breast cancers are characterized by Th2-associated microenvironment","volume":"15","author":"Guo","year":"2024","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2019.1624130","article-title":"A multivariate Th17 metagene for prognostic stratification in T cell non-inflamed triple negative breast cancer","volume":"8","author":"Faucheux","year":"2019","journal-title":"Oncoimmunology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI139905","article-title":"Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity","volume":"131","author":"No\u00ebl","year":"2021","journal-title":"J Clin Invest"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.3390\/ijms21175948","article-title":"High numbers and densities of PD1(+) T-follicular helper cells in triple-negative breast cancer draining lymph nodes are associated with lower survival","volume":"21","author":"Bronsert","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41467-022-29753-z","article-title":"T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy","volume":"13","author":"Garaud","year":"2022","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25208","article-title":"Oncodriver inhibition and CD4(+) Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: Implications for combining immune and targeted therapies","volume":"9","author":"Rosemblit","year":"2018","journal-title":"Oncotarget"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2022.04.034","article-title":"Immunogenomic landscape analyses of immune molecule signature-based risk panel for patients with triple-negative breast cancer","volume":"28","author":"Liu","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2022.2170779","article-title":"The tumor microenvironment and triple-negative breast cancer aggressiveness: Shedding light on mechanisms and targeting","volume":"26","author":"Furukawa","year":"2022","journal-title":"Expert Opin Ther Targets"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34084","article-title":"Regulatory T cells: Their role in triple-negative breast cancer progression and metastasis","volume":"128","author":"Malla","year":"2022","journal-title":"Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s285128","article-title":"Accumulation of regulatory T cells in triple negative breast cancer can boost immune disruption","volume":"13","author":"Zahran","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/s41467-021-21297-y","article-title":"Common clonal origin of conventional T cells and induced regulatory T cells in breast cancer patients","volume":"12","author":"Xydia","year":"2021","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.3390\/cancers14092138","article-title":"The effect of intratumoral interrelation among FOXP3+ regulatory T cells on treatment response and survival in triple-negative breast cancer","volume":"14","author":"Goda","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-23-0613","article-title":"CD25high effector regulatory T cells hamper responses to PD-1 blockade in triple-negative breast cancer","volume":"83","author":"Fattori","year":"2023","journal-title":"Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1263537","article-title":"Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer","volume":"14","author":"Huang","year":"2023","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.702726","article-title":"Regulatory T cells: Barriers of immune infiltration into the tumor microenvironment","volume":"12","author":"Scott","year":"2021","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/cancers13061440","article-title":"CTLA-4 in regulatory T cells for cancer immunotherapy","volume":"13","author":"Sobhani","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.679517","article-title":"IDO inhibition facilitates antitumor immunity of V\u03b39V\u03b42 T cells in triple-negative breast cancer","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00447-1","article-title":"Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through Fc\u03b3R engagement and type I interferon signaling","volume":"3","author":"Yofe","year":"2022","journal-title":"Nat Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218175","article-title":"BMP9 potentiates immunotherapy in triple-negative breast cancer by suppressing Tregs infiltration via the PRKDC-CCL2 axis","volume":"639","author":"You","year":"2026","journal-title":"Cancer Lett"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.02.029","article-title":"Caloric restriction impairs regulatory T cells within the tumor microenvironment after radiation and primes effector T cells","volume":"110","author":"Manukian","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.32604\/biocell.2023.027414","article-title":"M2 macrophages predicted the prognosis of breast cancer by combing a novel immune cell signature and promoted cell migration and invasion of cancer cells in vitro","volume":"48","author":"Xia","year":"2024"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0273044","article-title":"Triple-negative breast cancer influences a mixed M1\/M2 macrophage phenotype associated with tumor aggressiveness","volume":"17","author":"Pe","year":"2022","journal-title":"PloS One"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.772615","article-title":"Tumor-associated macrophages: key players in triple-negative breast cancer","volume":"12","author":"Qiu","year":"2022","journal-title":"Front Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00018-023-04810-y","article-title":"G6PD activation in TNBC cells induces macrophage recruitment and M2 polarization to promote tumor progression","volume":"80","author":"Li","year":"2023","journal-title":"Cell Mol Life Sci"},{"key":"B60","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s42003-023-04525-7","article-title":"Tissue-resident macrophages are major tumor-associated macrophage resources, contributing to early TNBC development, recurrence, and metastases","volume":"6","author":"Hirano","year":"2023","journal-title":"Commun Biol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114298","article-title":"B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy","volume":"183","author":"Cheng","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/s41467-025-67964-2","article-title":"Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers","volume":"17","author":"Pedroza","year":"2026","journal-title":"Nat Commun"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-21-3714","article-title":"Chemotherapy coupled to macrophage inhibition induces T-cell and B-cell infiltration and durable regression in triple-negative breast cancer","volume":"82","author":"Singh","year":"2022","journal-title":"Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-25-4236","article-title":"CSF1R inhibition with chemotherapy relieves systemic immune suppression in patients with metastatic triple-negative breast cancer and boosts anti-PD-1 efficacy in transgenic mammary tumors","volume":"32","author":"Poissonnier","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1097\/ms9.0000000000003269","article-title":"Neutrophils as key regulators of tumor microenvironment in breast cancer: a focus on N1 and N2 polarization","volume":"87","author":"Obeagu","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03248-8","article-title":"Intratumoral pro-oxidants promote cancer immunotherapy by recruiting and reprogramming neutrophils to eliminate tumors","volume":"72","author":"Ralph","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B67","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13058-023-01676-7","article-title":"Neutrophils in triple-negative breast cancer: an underestimated player with increasingly recognized importance","volume":"25","author":"Zheng","year":"2023","journal-title":"Breast Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.3389\/fimmu.2025.1593156","article-title":"Tumor-associated neutrophils in breast cancer: an angel or a devil","volume":"16","author":"Wen","year":"2025"},{"key":"B69","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41392-025-02242-7","article-title":"Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity","volume":"10","author":"Zhou","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B70","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12916-020-01817-1","article-title":"Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies","volume":"18","author":"Cupp","year":"2020","journal-title":"BMC Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2023.104598","article-title":"Neutrophil-to-lymphocyte ratio an inflammatory biomarker, and prognostic marker in heart failure, cardiovascular disease and chronic inflammatory diseases: new insights for a potential predictor of anti-cytokine therapy responsiveness","volume":"150","author":"Garc\u00eda-Escobar","year":"2023","journal-title":"Microvasc Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1065606","article-title":"The predictive value of neutrophil-to-lymphocyte ratio for overall survival and pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy","volume":"12","author":"Gao","year":"2022","journal-title":"Front Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-2748","article-title":"Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2-negative metastatic breast cancer","volume":"23","author":"Schott","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.659996","article-title":"Triple-negative breast cancer cells recruit neutrophils by secreting TGF-\u03b2 and CXCR2 ligands","volume":"12","author":"SenGupta","year":"2021","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1243-8","article-title":"A window-of-opportunity trial of the CXCR1\/2 inhibitor reparixin in operable HER-2-negative breast cancer","volume":"22","author":"Goldstein","year":"2020","journal-title":"Breast Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06367-5","article-title":"A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)","volume":"190","author":"Goldstein","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.7150\/thno.15625","article-title":"Role of the CXCL8-CXCR1\/2 axis in cancer and inflammatory diseases","volume":"7","author":"Ha","year":"2017","journal-title":"Theranostics"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl4414","article-title":"Immature natural killer cells promote progression of triple-negative breast cancer","volume":"15","author":"Thacker","year":"2023","journal-title":"Sci Transl Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004825","article-title":"ELK3 modulates the antitumor efficacy of natural killer cells against triple negative breast cancer by regulating mitochondrial dynamics","volume":"10","author":"Park","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.3389\/fimmu.2025.1595533","article-title":"Recent advances in tumor immunotherapy based on NK cells","volume":"16","author":"Chen","year":"2025"},{"key":"B81","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/cells13050451","article-title":"Building a better defense: expanding and improving natural killer cells for adoptive cell therapy","volume":"13","author":"Maia","year":"2024","journal-title":"Cells"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2026.2644899","article-title":"CTL-NK signature based on immune gene profiling and IHC predicts clinical outcomes in triple-negative breast cancer","volume":"44","author":"Alfahdawi","year":"2026","journal-title":"Cancer Invest"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1200282","article-title":"Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.17504\/protocols.io.5qpvo3y9xv4o\/v1","article-title":"Metabolic programs drive function of therapeutic NK cells in hypoxic tumor environments","volume":"10","author":"Kennedy","year":"2024","journal-title":"Sci Adv"},{"key":"B85","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1038\/s41467-022-31764-9","article-title":"Hypoxia induces HIF1\u03b1-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy","volume":"13","author":"Ma","year":"2022","journal-title":"Nat Commun"},{"key":"B86","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13058-025-02003-y","article-title":"Phenotypes and cytokines of NK cells in triple-negative breast cancer resistant to checkpoint blockade immunotherapy","volume":"27","author":"Wang","year":"2025","journal-title":"Breast Cancer Res"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1038\/s41467-023-37727-y","article-title":"Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer","volume":"14","author":"Palakurthi","year":"2023","journal-title":"Nat Commun"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03293-3","article-title":"Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer","volume":"72","author":"Kajihara","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5387","article-title":"Regulation of DNA-PK activity promotes the progression of TNBC via enhancing the immunosuppressive function of myeloid-derived suppressor cells","volume":"12","author":"Han","year":"2023","journal-title":"Cancer Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.20937","article-title":"Subtype-specific heterogeneity of myeloid-derived suppressor cells in breast cancer: current insights and future directions","volume":"14","author":"Gong","year":"2026","journal-title":"PeerJ"},{"key":"B91","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","article-title":"Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy","volume":"21","author":"Wu","year":"2022","journal-title":"Mol Cancer"},{"key":"B92","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s43556-025-00372-6","article-title":"Delta-like ligand 4 mediated myeloid-derived suppressor cell metabolic reprogramming promotes neoadjuvant therapy resistance in titin-inactivated triple-negative breast cancer","volume":"6","author":"Yang","year":"2025","journal-title":"Mol BioMed"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2026.218690","article-title":"Immunotherapy resistance in triple-negative breast cancer: mechanisms and emerging therapeutic strategies","volume":"658","author":"Zhao","year":"2026","journal-title":"Cancer Lett"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.34133\/research.0915","article-title":"Gene signature-based drug screening reveals ponatinib enhances immunotherapy efficacy in triple-negative breast cancer by reversing MDSC-mediated immunosuppressive tumor microenvironment","volume":"8","author":"Wang","year":"2025","journal-title":"Res (Wash D C)"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.633205","article-title":"Natural killer cell interactions with myeloid derived suppressor cells in the tumor microenvironment and implications for cancer immunotherapy","volume":"12","author":"Zalfa","year":"2021","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000450","article-title":"PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations","volume":"8","author":"Fabian","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B97","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41523-025-00814-y","article-title":"Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy","volume":"11","author":"Cortes","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102817","article-title":"Evolving immunotherapeutic solutions for triple-negative breast carcinoma","volume":"130","author":"Wu","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study","volume":"34","author":"Nanda","year":"2016","journal-title":"J Clin Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102964","article-title":"The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab","volume":"9","author":"Buisseret","year":"2024","journal-title":"ESMO Open"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.3390\/diagnostics14232672","article-title":"Impact of neoadjuvant therapy on PD-L1 expression in triple-negative breast cancer and correlation with clinicopathological factors","volume":"14","author":"Ilieva","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B102","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1038\/s41467-021-25962-0","article-title":"Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer","volume":"12","author":"Hammerl","year":"2021","journal-title":"Nat Commun"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac136","article-title":"A comprehensive profiling of the immune microenvironment of breast cancer brain metastases","volume":"24","author":"Griguolo","year":"2022","journal-title":"Neuro Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104417","article-title":"Next-generation biomarkers for prognostic and potential therapeutic enhancement in triple negative breast cancer","volume":"201","author":"Banerjee","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"9256","DOI":"10.1038\/s41598-023-36517-2","article-title":"Effects of tumor-infiltrating lymphocytes on nonresponse rate of neoadjuvant chemotherapy in patients with invasive breast cancer","volume":"13","author":"Qian","year":"2023","journal-title":"Sci Rep"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3390\/biomedicines10051130","article-title":"Immune checkpoint blockades in triple-negative breast cancer: Current state and molecular mechanisms of resistance","volume":"10","author":"Kim","year":"2022","journal-title":"Biomedicines"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41467-024-45160-y","article-title":"The anti-PD-L1\/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0100","article-title":"Small-cell breast carcinoma with response to atezolizumab: a case report","author":"Stimes","year":"2022","journal-title":"Immunotherapy"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121578","article-title":"Photothermal MnO(2) nanoparticles boost chemo-photothermal therapy-induced immunogenic cell death in tumor immunotherapy","volume":"617","author":"Chen","year":"2022","journal-title":"Int J Pharm"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.11.001","article-title":"Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer","volume":"39","author":"Koh","year":"2021","journal-title":"Cancer Cell"},{"key":"B113","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41420-022-00893-x","article-title":"A single-cell transcriptomic landscape of innate and adaptive intratumoral immunity in triple negative breast cancer during chemo- and immunotherapies","volume":"8","author":"Carpen","year":"2022","journal-title":"Cell Death Discov"},{"key":"B114","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.32604\/biocell.2025.072360","article-title":"VCA augments doxorubicin efficacy in triple-negative breast cancer: Evidence for multi-pathway synergism","volume":"49","author":"Hong","year":"2025"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.32604\/biocell.2024.050868","article-title":"LA-D-B1, a novel abemaciclib derivative, exerts anti-breast cancer effects through CDK4\/6","volume":"48","author":"Ma","year":"2024"},{"key":"B117","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3892\/ijo.2022.5385","article-title":"Research progress on immunotherapy in triple\u2011negative breast cancer (Review)","volume":"61","author":"Zhang","year":"2022","journal-title":"Int J Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-22-0012","article-title":"Tinengotinib (TT-00420), a novel spectrum-selective small-molecule kinase inhibitor, is highly active against triple-negative breast cancer","volume":"22","author":"Peng","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1201\/9780429263545-3","article-title":"Combination therapies to improve the efficacy of immunotherapy in triple-negative breast cancer","volume":"22","author":"Ale\u010dkovi\u0107","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-024-01603-4","article-title":"Neoadjuvant talazoparib in patients with germline BRCA1\/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status","volume":"31","author":"Telli","year":"2024","journal-title":"Breast Cancer"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-023-01451-8","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"B122","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41523-022-00471-5","article-title":"STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer","volume":"8","author":"Pantelidou","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B123","doi-asserted-by":"publisher","first-page":"11271","DOI":"10.3390\/ijms262311271","article-title":"Targeting DNA damage response and immune crosstalk in cancer: Mechanistic insights and therapeutic opportunities","volume":"26","author":"Marcut","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/edbk_351186","article-title":"Integrating immunotherapy into the treatment landscape for patients with triple-negative breast cancer","volume":"42","author":"Dixon-Douglas","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.628690","article-title":"Activation of PI3K\/AKT\/mTOR pathway causes drug resistance in breast cancer","volume":"12","author":"Dong","year":"2021","journal-title":"Front Pharmacol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13046-018-0741-3","article-title":"The anti-tumor efficacy of CDK4\/6 inhibition is enhanced by the combination with PI3K\/AKT\/mTOR inhibitors through impairment of glucose metabolism in TNBC cells","volume":"37","author":"Cretella","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"B127","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.3390\/cancers17132232","article-title":"The PI3K\/Akt\/mTOR signaling pathway in triple-negative breast cancer: A resistance pathway and a prime target for targeted therapies","volume":"17","author":"Hassan","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B128","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.3390\/cancers16122189","article-title":"Beyond anti-PD-1\/PD-L1: Improving immune checkpoint inhibitor responses in triple-negative breast cancer","volume":"16","author":"Bullock","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B129","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","article-title":"Recent advances in targeted strategies for triple-negative breast cancer","volume":"16","author":"Zhu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110729","article-title":"Everolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer","volume":"109","author":"Li","year":"2023","journal-title":"Cell Signal"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100506","article-title":"MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression","volume":"3","author":"Rodriguez","year":"2022","journal-title":"Cell Rep Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.134290","article-title":"MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC","volume":"5","author":"Franklin","year":"2020","journal-title":"JCI Insight"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.32604\/biocell.2025.071569","article-title":"ROS regulation by natural products: A promising therapeutic approach for breast cancer","volume":"49","author":"Shuai","year":"2025"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.38212\/2224-6614.3387","article-title":"Curcumin-induced antitumor effects on triple-negative breast cancer patient-derived xenograft tumor mice through inhibiting salt-induced kinase-3 protein","volume":"29","author":"Cheng","year":"2021","journal-title":"J Food Drug Anal"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2021.104423","article-title":"Resveratrol attenuates TNBC lung metastasis by down-regulating PD-1 expression on pulmonary T cells and converting macrophages to M1 phenotype in a murine tumor model","volume":"368","author":"Han","year":"2021","journal-title":"Cell Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2025.155823","article-title":"Triptolide's impact on ACER1 signaling: Inducing autophagy for triple-negative breast cancer suppression","volume":"266","author":"Huang","year":"2025","journal-title":"Pathol Res Pract"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2020.113249","article-title":"The signaling pathways and targets of traditional Chinese medicine and natural medicine in triple-negative breast cancer","volume":"264","author":"Yang","year":"2021","journal-title":"J Ethnopharmacol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.920514","article-title":"Curcumin and its nano-formulations: Defining triple-negative breast cancer targets through network pharmacology, molecular docking, and experimental verification","volume":"13","author":"Deng","year":"2022","journal-title":"Front Pharmacol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2567150","article-title":"Curcumin targeting NF-\u03baB\/Ubiquitin-Proteasome-System axis ameliorates muscle atrophy in triple-negative breast cancer cachexia mice","volume":"2022","author":"Zhang","year":"2022","journal-title":"Mediators Inflammation"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2022.01.010","article-title":"Metformin inhibits the tumor-promoting effect of low-dose resveratrol, and enhances the anti-tumor activity of high-dose resveratrol by increasing its reducibility in triple negative breast cancer","volume":"180","author":"Cheng","year":"2022","journal-title":"Free Radic Biol Med"},{"key":"B141","doi-asserted-by":"publisher","first-page":"42","DOI":"10.37349\/etat.2023.00122","article-title":"Enhancement of reactive oxygen species production in triple negative breast cancer cells treated with electric pulses and resveratrol","volume":"4","author":"Giri","year":"2023","journal-title":"Explor Target Antitumor Ther"},{"key":"B142","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13046-024-03133-5","article-title":"Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer","volume":"43","author":"Chen","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s601715","article-title":"Anti-cancer research progress of triptolide: Mechanisms of action, structural modifications, nanodelivery systems and clinical challenges","volume":"20","author":"Li","year":"2026","journal-title":"Drug Des Devel Ther"},{"key":"B144","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2147\/bctt.s511059","article-title":"Exploration of traditional Chinese medicine comprehensive treatment of triple negative breast cancer based on molecular pathological mechanism","volume":"17","author":"Zhu","year":"2025","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e28385","article-title":"Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer","volume":"10","author":"Schipilliti","year":"2024","journal-title":"Heliyon"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2508959","article-title":"Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"},{"key":"B147","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.3390\/cancers15153801","article-title":"Systemic therapy for metastatic triple negative breast cancer: Current treatments and future directions","volume":"15","author":"Morrison","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2257885","article-title":"The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan","volume":"23","author":"Schreiber","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"B150","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1186\/s12964-024-01893-3","article-title":"Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells","volume":"22","author":"Oh","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B151","doi-asserted-by":"publisher","first-page":"194","DOI":"10.15698\/cst2025.08.311","article-title":"Datopotamab deruxtecan induces hallmarks of immunogenic cell death","volume":"9","author":"Forveille","year":"2025","journal-title":"Cell Stress"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.12701\/jyms.2026.43.17","article-title":"Immunotherapy in triple-negative breast cancer: mechanisms of resistance and emerging approaches: a narrative review","volume":"43","author":"Koh","year":"2026","journal-title":"J Yeungnam Med Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1887760\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:53:22Z","timestamp":1787669602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1887760\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":152,"alternative-id":["10.3389\/fimmu.2026.1887760"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1887760","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"article-number":"1887760"}}